Skip to Content

Acasti Pharma Inc Class A ACST

Morningstar Rating
$2.90 +0.02 (0.69%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACST is trading at a 71% discount.
Price
$2.86
Fair Value
$9.98
Uncertainty
Extreme
1-Star Price
$87.95
5-Star Price
$9.80
Economic Moat
Xbqt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACST is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.88
Day Range
$2.873.16
52-Week Range
$1.723.84
Bid/Ask
$2.58 / $2.95
Market Cap
$27.26 Mil
Volume/Avg
8,424 / 28,018

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
32

Valuation

Metric
ACST
Price/Earnings (Normalized)
Price/Book Value
0.42
Price/Sales
Price/Cash Flow
Price/Earnings
ACST

Financial Strength

Metric
ACST
Quick Ratio
14.73
Current Ratio
15.19
Interest Coverage
Quick Ratio
ACST

Profitability

Metric
ACST
Return on Assets (Normalized)
−8.66%
Return on Equity (Normalized)
−10.19%
Return on Invested Capital (Normalized)
−11.01%
Return on Assets
ACST
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFggtdflxhBsj$557.8 Bil
VRTX
Vertex Pharmaceuticals IncDrksqdkfCcmnwb$104.7 Bil
REGN
Regeneron Pharmaceuticals IncRcfkhfcfNjrjlt$99.6 Bil
MRNA
Moderna IncPbslbztKtl$38.8 Bil
ARGX
argenx SE ADRQpcwvbhylQslq$21.4 Bil
BNTX
BioNTech SE ADRWzwqldmGjgwm$21.3 Bil
ALNY
Alnylam Pharmaceuticals IncLdqzzllfbPzhtt$18.4 Bil
BMRN
Biomarin Pharmaceutical IncRyhypwgpwCgzwtj$17.5 Bil
RPRX
Royalty Pharma PLC Class AHfmpnkwrdWyffpm$12.4 Bil
INCY
Incyte CorpGtzrkfmfJmnjgqs$11.9 Bil

Sponsor Center